Organon (OGN) Receivables - Other (2020 - 2023)
Organon (OGN) recorded quarterly Receivables - Other of $344.0 million in Q1 2023, down 8.02% quarter-over-quarter from $374.0 million in Q4 2022, and down 3.91% on a YoY basis from $358.0 million in Q1 2022.
Organon (OGN) Receivables - Other (2020 - 2023) Analysis & Trends
Organon's Receivables - Other history runs 4 years deep, the most recent figure standing at $344.0 million for Q1 2023.
- In Q1 2023, Receivables - Other fell 3.91% year-over-year to $344.0 million; the TTM figure through Mar 2023 stood at $344.0 million (down 3.91% YoY), while the FY2022 annual figure was $374.0 million, down 7.2% from the prior year.
- Receivables - Other was $344.0 million for Q1 2023 at Organon, down from $374.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $991.0 million in Q2 2021 to a low of $189.0 million in Q4 2020.
- Historically, Receivables - Other has averaged $491.0 million across 4 years, with a median of $403.0 million in 2021.
- The sharpest annual moves came in 2021 and 2022: Receivables - Other jumped 113.23% in 2021, then plunged 56.21% in 2022.
- A 4-year view of Receivables - Other shows it stood at $189.0 million in 2020, then soared by 113.23% to $403.0 million in 2021, then slipped by 7.2% to $374.0 million in 2022, then fell by 8.02% to $344.0 million in 2023.
- The last three Receivables - Other figures came in at $344.0 million (Q1 2023), $374.0 million (Q4 2022), and $412.0 million (Q3 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 344.00 Mn |
| Mar 31, 2023 | 344.00 Mn |
| Dec 31, 2022 | 374.00 Mn |
| Dec 31, 2022 | 374.00 Mn |
| Sep 30, 2022 | 412.00 Mn |
| Sep 30, 2022 | 412.00 Mn |
| Jun 30, 2022 | 434.00 Mn |
| Jun 30, 2022 | 434.00 Mn |
| Mar 31, 2022 | 358.00 Mn |
| Mar 31, 2022 | 358.00 Mn |
| Dec 31, 2021 | 403.00 Mn |
| Dec 31, 2021 | 403.00 Mn |
| Sep 30, 2021 | 914.00 Mn |
| Sep 30, 2021 | 914.00 Mn |
| Jun 30, 2021 | 991.00 Mn |
| Jun 30, 2021 | 991.00 Mn |
| Dec 31, 2020 | 189.00 Mn |
| Dec 31, 2020 | 189.00 Mn |